Efficacy of AEMCOLO (Rifamycin SV MMX) in the Treatment of Small Intestinal Bacterial Overgrowth (SIBO)
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
Open label interventional randomized pilot study utilizing two dosing regimens of AEMCOLO.
The goal of this study is to evaluate effectiveness of a novel antibiotic, AEMCOLO (Rifamycin
SV MMX) in the treatment of Small intestinal bacterial overgrowth (SIBO).